We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: progression-free survival
MedXY News
EnglishTag

progression-free survival

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up
newstargeted therapyprogression-free survival

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

By MedXY|Sep 21, 2026

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients

Optimizing Outcomes in POEMS Syndrome: Real-World Insights on Autologous Stem Cell Transplantation from a Multicenter Study
Hematology-Oncology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
progression-free survival
autologous stem-cell transplantation

Optimizing Outcomes in POEMS Syndrome: Real-World Insights on Autologous Stem Cell Transplantation from a Multicenter Study

By MedXY|Aug 5, 2026

This multicenter study evaluates autologous stem cell transplantation (ASCT) in POEMS syndrome, showing significant hematologic response, durable survival, and manageable toxicity, highlighting ASCT’s pivotal role in treatment.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
newsbreast cancerprogression-free survival

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY|Aug 18, 2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
newsbreast cancerprogression-free survival

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY|Aug 18, 2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source
Hematology-OncologyCLLmeasurable residual disease

MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source

By MedXY|May 4, 2026

A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.

Five-Year POLARIX Follow-Up: Polatuzumab-R-CHP Improves Long-Term PFS in Frontline DLBCL — What Clinicians Need to Know
Hematology-OncologyDLBCLprogression-free survival

Five-Year POLARIX Follow-Up: Polatuzumab-R-CHP Improves Long-Term PFS in Frontline DLBCL — What Clinicians Need to Know

By MedXY|Dec 11, 2025

At five years, pola‑R‑CHP showed a sustained progression‑free survival benefit versus R‑CHOP in newly diagnosed intermediate‑/high‑risk DLBCL (HR 0.77), with similar long‑term tolerability and no statistically significant overall survival d

Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival
GastroenterologyLipid Metabolismolverembatinib

Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival

By MedXY|Nov 5, 2025

Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival
GastroenterologyBiliary tract canceroverall survival

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

By MedXY|Oct 28, 2025

This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need

Imaging-Detected Extranodal Extension as a Predictor of Distant Recurrence in HPV-Positive Oropharyngeal Cancer
newsExtranodal ExtensionHPV-positive oropharyngeal cancer

Imaging-Detected Extranodal Extension as a Predictor of Distant Recurrence in HPV-Positive Oropharyngeal Cancer

By MedXY|Oct 22, 2025

Imaging-based extranodal extension (iENE) in HPV-positive oropharyngeal cancer predicts higher rates of distant metastases and decreased progression-free survival, highlighting its prognostic significance and potential role in refining stag

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy
Hematology-Oncologycirculating tumor cellsdaratumumab

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

By MedXY|Oct 14, 2025

Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial
Hematology-Oncologyautologous stem-cell transplantationmultiple myeloma

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

By MedXY|Oct 14, 2025

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in adva

Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients
Hematology-OncologyIbrutinibImmunochemotherapy

Ibrutinib-Rituximab versus Immunochemotherapy: A Paradigm Shift in First-Line Treatment for Older Mantle Cell Lymphoma Patients

By MedXY|Oct 10, 2025

The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherap

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial
Clinical Updatesclinical trialneuroendocrine tumors

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

By MedXY|Oct 6, 2025

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer
Clinical UpdatesCarboplatinEverolimus

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer

By MedXY|Oct 6, 2025

A phase 2 study shows adding everolimus to carboplatin significantly improves progression-free survival in advanced TNBC with manageable safety profile, indicating a potential new treatment avenue.

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma
Clinical UpdatesFollicular lymphomalenalidomide

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma

By MedXY|Oct 5, 2025

This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising fro

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial
newsDoxorubicinmaintenance therapy

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY|Oct 2, 2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safet

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA
Clinical Updatesdaratumumabminimal residual disease

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

By MedXY|Oct 1, 2025

Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial
Clinical UpdatescarfilzomibDexamethasone

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY|Oct 1, 2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival
Clinical Updatesbreast cancerCDK4/6 inhibitor

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

By MedXY|Oct 1, 2025

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure